Phase 2 Auricular Point Stimulation Plus Dexamethasone for Chemotherapy-Induced Nausea and Vomiting (NCT07537699)
Summary
NIH ClinicalTrials.gov registered a Phase 2 clinical trial (NCT07537699) evaluating auricular point stimulation combined with dexamethasone for preventing chemotherapy-induced nausea and vomiting in breast cancer patients receiving docetaxel plus cyclophosphamide. The single-arm study will track nausea, vomiting, appetite, and gastrointestinal function from Day 1 through Day 5 of chemotherapy. Participating institutions and investigators must conduct the trial in accordance with the registered protocol, IRB oversight, and informed consent requirements.
What changed
NIH ClinicalTrials.gov added a new Phase 2 clinical trial registration (NCT07537699) for a study investigating auricular point stimulation (auricular acupressure with bean seeds) combined with intravenous dexamethasone as a preventive antiemetic regimen for chemotherapy-induced nausea and vomiting. The trial targets breast cancer patients undergoing adjuvant chemotherapy with docetaxel plus cyclophosphamide.
For clinical investigators, research institutions, and healthcare providers considering participation, this registration establishes the official protocol framework including participant eligibility, intervention methodology, daily self-stimulation procedures (Days 1-5), symptomatic tracking requirements, and provisions for rescue antiemetics. Compliance with the registered protocol is required for IRB approval and FDA regulatory oversight of the study conduct.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide
Phase 2 NCT07537699 Kind: PHASE2 Apr 17, 2026
Abstract
The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by docetaxel combined with cyclophosphamide in breast cancer adjuvant chemotherapy. It will also learn about the safety and influence on gastrointestinal function of auricular point stimulation plus dexamethasone.
The main questions it aims to answer are:
Can auricular point stimulation plus dexamethasone effectively prevent or suppress nausea and vomiting induced by the docetaxel plus cyclophosphamide regimen? Can auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions caused by excessive use of antiemetic drugs?
Participants will:
Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be tem...
Conditions: Nausea and Vomiting Caused by Chemotherapy
Interventions: Auricular point stimulation plus dexamethasone
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.